Research Article

Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma

Table 2

SLC6A14 IHC staining intensity.

0: none ()1: weak ()2: moderate ()3: strong ()Total () value

Survival0.1181
54224879
 Events53620768
 Median survival
  days
633.0 (487.0–2532.0)733.0 (405.0–1247.0)595.0 (334.0–1281.0)366.0 (253.0–641.0)579.0 (419.0–962.0)
 2 Yr survival rate40.0% (0.0%–82.9%)51.2% (35.9%–66.5%)45.8% (25.9%–65.8%)0.0% 44.2% (33.1%–55.3%)
 Year 2 at risk22111034
Age of onset0.1099
53722872
 Mean (SD)73.0 (7.0)67.6 (10.6)66.5 (9.2)61.1 (9.0)66.9 (10.0)
 Median75.069.070.059.569.0
 Q1, Q374.0, 76.061.0, 75.060.0, 75.054.0, 68.060.0, 75.0
 Range (61.0–79.0) (37.0–85.0) (48.0–76.0) (50.0–76.0) (37.0–85.0)
 Median age of
  onset
75.0 (61.0–79.0)69.0 (64.0–73.0)70.0 (60.0–74.0)59.5 (50.0–69.0)69.0 (66.0–72.0)0.0978
Sex0.2142
 Missing084315
 Female1 (20.0%)25 (59.5%)10 (41.7%)3 (37.5%)39 (49.4%)
 Male4 (80.0%)17 (40.5%)14 (58.3%)5 (62.5%)40 (50.6%)
Obesity0.2358
 Missing1219536
 BMI < 302 (50.0%)24 (82.8%)17 (89.5%)4 (66.7%)47 (81.0%)
 BMI 30+2 (50.0%)5 (17.2%)2 (10.5%)2 (33.3%)11 (19.0%)
Diabetes self-reported0.6592
 Missing084315
 No DM5 (100.0%)33 (78.6%)18 (75.0%)6 (75.0%)62 (78.5%)
 DM0 (0.0%)9 (21.4%)6 (25.0%)2 (25.0%)17 (21.5%)
Pancreatitis self-reported0.8622
 Missing084315
 No pancreatitis 4 (80.0%)31 (73.8%)18 (75.0%)7 (87.5%)60 (75.9%)
 Pancreatitis1 (20.0%)11 (26.2%)6 (25.0%)1 (12.5%)19 (24.1%)
Tumor grade0.5917
 20 (0.0%)8 (16.0%)1 (3.6%)1 (9.1%)10 (10.6%)
 34 (80.0%)31 (62.0%)20 (71.4%)6 (54.5%)61 (64.9%)
 41 (20.0%)11 (22.0%)7 (25.0%)4 (36.4%)23 (24.5%)